- Home
- BIOA vs EBS Comparison
BIOA vs EBS Comparison
Compare BIOA & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIOA | EBS |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 303.3M |
| IPO Year | 2024 | 2006 |
Fundamental Metrics
Financial Performance| Metric | BIOA | EBS |
|---|---|---|
| Price | $5.44 | $5.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $28.89 | $10.00 |
| AVG Volume (30 Days) | 739.5K | ★ 1.1M |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 66.21 | ★ 125.83 |
| EPS | ★ N/A | N/A |
| Revenue | $8,995,000.00 | ★ $742,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $83.62 | $7.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.81 | $4.36 |
| 52 Week High | $25.96 | $14.06 |
Technical Indicators
Market Signals| Indicator | BIOA | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 40.18 |
| Support Level | $4.81 | $5.51 |
| Resistance Level | $6.30 | $6.83 |
| Average True Range (ATR) | 0.47 | 0.45 |
| MACD | 0.10 | -0.06 |
| Stochastic Oscillator | 35.87 | 21.73 |
Price Performance
Historical ComparisonAbout BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.